News

The accumulation of one particular protein in the brain is at the basis of three very different age-related conditions. Until recently, nobody understood how this was possible. Research by the Laboratory for Neurobiology and Gene Therapy now reveals that the shape of the protein determines the clinical picture.

A landmark partnership has been announced today between the University of Oxford and the biopharmaceutical company AstraZeneca. The partnership will facilitate the further development and large-scale manufacturing of the COVID-19 vaccine candidate, ChAdOx1 nCoV-19, currently in clinical trials.

Using a precise technique known as scanning tunneling microscopy, researchers may have provided a powerful quality control mechanism for pharmaceuticals.

New research has revealed how APOE4 — a genetic culprit for Alzheimer’s disease — triggers leaks in the brain’s plumbing system, which could explain how it drives cognitive decline.

In a study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however further conformational studies are advised.

An anti-inflammatory drug developed 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19.

Scientists have been using Frontera, the fastest supercomputers at any university in the world, and Longhorn, an IBM/NVIDIA system at the Texas Advanced Computing Center (TACC), to rapidly generate molecular models of compounds relevant for COVID-19, in collaboration with medicinal chemists.

A team of researchers has found candidate genes that could eventually be used to manufacture the cancer drug Taxol more quickly and efficiently.

An important goal of early-phase clinical studies is to uncover a drug’s possible side effects. But despite FDA guidelines seeking to standardize this reporting, a study finds significant variation in how drug side effects are reported.

A study from Dr. Bernard Jasmin’s laboratory, published today in Nature Communications shows that a protein understudy points the way toward novel therapies for Duchenne muscular dystrophy.